Abstract
The in vitro activity of the new carbapenem, meropenem (MEPM) was tested in comparison with imipenem (IPM), ceftazidime, cefotaxime, latamoxef and flomoxef. MEPM showed good activity against a broad spectrum of gram-positive and gram-negative standard bacteria, including Pseudomonas aeruginosa. The activity of MEPM against gram-positive cocci was about one-fourth that of IPM. MEPM was highly active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except for 25% of Serratia marcescens isolates, at a concentration of 0.78 µg/ml. MEPM also showed a high activity against P. aeruginosa, its activity being two-fold higher than that of IPM. Against anaerobes, MEPM also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. MEPM also showed bactericidal activity against clinical isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Proteus vulgaris and P. aeruginosa at the MIC or at concentrations slightly above the MIC. MEPM was quite stable against various types of β-lactamase, but was hydrolyzed by X. maltophilia L-1 type β-lactamase, as were IPM and other β-lactams. This high degree of stability was responsible for the potent activity of MEPM against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and P. vulgaris.
| Original language | English |
|---|---|
| Pages (from-to) | 1-15 |
| Number of pages | 15 |
| Journal | Chemotherapy |
| Volume | 40 |
| DOIs | |
| Publication status | Published - Jan 1 1992 |
| Externally published | Yes |
Fingerprint
Keywords
- Meropenem
- β-lactamase
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
- Drug Discovery
- Oncology
Cite this
In vitro antibacterial activity of meropenem, a new carbapenem antibiotic. / Sumita, Yoshihiro; Mitsuhashi, Susumu; Inoue, Matsuhisa; Inoue, Matsuhisa.
In: Chemotherapy, Vol. 40, 01.01.1992, p. 1-15.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - In vitro antibacterial activity of meropenem, a new carbapenem antibiotic
AU - Sumita, Yoshihiro
AU - Mitsuhashi, Susumu
AU - Inoue, Matsuhisa
AU - Inoue, Matsuhisa
PY - 1992/1/1
Y1 - 1992/1/1
N2 - The in vitro activity of the new carbapenem, meropenem (MEPM) was tested in comparison with imipenem (IPM), ceftazidime, cefotaxime, latamoxef and flomoxef. MEPM showed good activity against a broad spectrum of gram-positive and gram-negative standard bacteria, including Pseudomonas aeruginosa. The activity of MEPM against gram-positive cocci was about one-fourth that of IPM. MEPM was highly active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except for 25% of Serratia marcescens isolates, at a concentration of 0.78 µg/ml. MEPM also showed a high activity against P. aeruginosa, its activity being two-fold higher than that of IPM. Against anaerobes, MEPM also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. MEPM also showed bactericidal activity against clinical isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Proteus vulgaris and P. aeruginosa at the MIC or at concentrations slightly above the MIC. MEPM was quite stable against various types of β-lactamase, but was hydrolyzed by X. maltophilia L-1 type β-lactamase, as were IPM and other β-lactams. This high degree of stability was responsible for the potent activity of MEPM against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and P. vulgaris.
AB - The in vitro activity of the new carbapenem, meropenem (MEPM) was tested in comparison with imipenem (IPM), ceftazidime, cefotaxime, latamoxef and flomoxef. MEPM showed good activity against a broad spectrum of gram-positive and gram-negative standard bacteria, including Pseudomonas aeruginosa. The activity of MEPM against gram-positive cocci was about one-fourth that of IPM. MEPM was highly active against gram-negative bacteria, inhibiting all Enterobacteriaceae, except for 25% of Serratia marcescens isolates, at a concentration of 0.78 µg/ml. MEPM also showed a high activity against P. aeruginosa, its activity being two-fold higher than that of IPM. Against anaerobes, MEPM also had the best activity of the β-lactams tested. The compound was inactive against methicillin-resistant staphylococci, Enterococcus faecium, Xanthomonas maltophilia and Flavobacterium spp., as were the other β-lactams. MEPM also showed bactericidal activity against clinical isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Proteus vulgaris and P. aeruginosa at the MIC or at concentrations slightly above the MIC. MEPM was quite stable against various types of β-lactamase, but was hydrolyzed by X. maltophilia L-1 type β-lactamase, as were IPM and other β-lactams. This high degree of stability was responsible for the potent activity of MEPM against β-lactamase-producing species such as Enterobacter cloacae, Citrobacter freundii and P. vulgaris.
KW - Meropenem
KW - β-lactamase
UR - http://www.scopus.com/inward/record.url?scp=0026633720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026633720&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.40.Supplement1_1
DO - 10.11250/chemotherapy1953.40.Supplement1_1
M3 - Article
AN - SCOPUS:0026633720
VL - 40
SP - 1
EP - 15
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
ER -